Nektar Therapeutics (NKTR) Earnings Analysis
Nektar Therapeutics (NKTR) next reports earnings on 2026-08-06, consensus EPS -1.94 USD. Last quarter (2026-03-12) it beat with EPS -1.78 USD vs -2.76 USD est (+35.5%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -8.23.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NKTR next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -1.94 USD |
| Revenue estimate | 0.01B |
NKTR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-12 | -1.78 USD | -2.76 USD | +35.5% | Beat |
| 2025-11-06 | -1.85 USD | -2.85 USD | +35.1% | Beat |
| 2025-08-07 | -2.95 USD | -3.13 USD | +5.8% | Beat |
| 2025-05-08 | -3.3 USD | -2.7 USD | -22.2% | Miss |
| 2025-03-12 | -2.25 USD | -1.95 USD | -15.4% | Miss |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
NKTR valuation and analyst view
| Trailing P/E | -8.23 |
|---|---|
| Trailing EPS | -6.3914 USD |
| Price / book | 2.98 |
| Dividend yield | 0.00% |
| Market cap | 1.35B |
| Analyst consensus | Buy (22 buy / 6 hold / 5 sell) |
| Avg price target | 141.67 USD |
Related research pages
Frequently asked questions
When is Nektar Therapeutics (NKTR)'s next earnings date?
Nektar Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -1.94 USD and revenue estimate of 0.01B.
Did NKTR beat earnings last quarter?
In its 2026-03-12 report, NKTR posted EPS of -1.78 USD versus a -2.76 USD estimate — a beat of 35.5%.
What is NKTR's earnings track record?
Over the last 5 reported quarters with consensus data, NKTR beat estimates 3 times (60%).
What is NKTR's current P/E ratio and EPS?
NKTR trades at a trailing P/E of -8.23 on trailing EPS of -6.391396271339185 USD.
What do analysts rate NKTR?
Analyst consensus is "Buy" across 33 ratings (0 strong buy, 22 buy, 6 hold, 5 sell, 0 strong sell). Average 12-month price target: 141.67 USD.